Sleep ap­nea biotech breathes easy with $62.5M fi­nanc­ing ahead of PhI­II tri­als for lead oral drug

Tra­di­tion­al care for ob­struc­tive sleep ap­nea in­volves CPAP, a cum­ber­some coun­ter­mea­sure in which pa­tients have air con­tin­u­ous­ly pushed through a mask they have to wear through the night. While there have been im­prove­ments to CPAP tech­nol­o­gy, it has re­mained the stan­dard of care for ob­struc­tive sleep ap­nea since its in­ven­tion just over 40 years ago.

How­ev­er, Cam­bridge-based biotech Ap­n­imed is now tout­ing that it may have an oral drug that could change that stan­dard, and it has won $62.5 mil­lion in Se­ries C fund­ing to fu­el an up­com­ing Phase III tri­al for said can­di­date to test that claim.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER